Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

BrainChild Bio, Inc. has closed a $116 million Series A financing to advance its CAR T cell therapies. The round was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.

PRIVATESep 08, 2026•about 3 hours ago

Amount Raised

$116 Million

Round Type

Series A

BiotechnologyHealth CareTherapeutics

Investors

Wrf CapitalSeattle Children’sUndisclosed Private Family Fund And Foundation

Description

BrainChild Bio, Inc. has secured $116 million in a Series A financing round to support its clinical trials for CAR T cell therapies. The financing will bolster the ILLUMINATE Phase 2 study for BCB-276, targeting a rare pediatric brain tumor. Funds will also aid in the development of BCB-214 for glioblastoma

Company Information

Company

BrainChild Bio

About

BrainChild Bio, Inc. is a clinical-stage biotechnology company focused on developing CAR T cell therapies aimed at treating tumors in the central nervous system. The company is advancing its investigational therapies for conditions such as diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor. With a foundation established on technology developed at Seattle Children's, BrainChild Bio is rapidly progressing toward clinical trials and regulatory approval for its innovative treatments.

Don't miss BrainChild Bio's next move

Get an email the moment BrainChild Bio raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for BrainChild Bio's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

BrainChild Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.